DZ2870A1 - Dérivés d'acide hydroxypipécolate-hydroxamique nouveaux, procédé pour leur préparation et compositi ons pharmaceutiques les contenant. - Google Patents

Dérivés d'acide hydroxypipécolate-hydroxamique nouveaux, procédé pour leur préparation et compositi ons pharmaceutiques les contenant.

Info

Publication number: DZ2870A1
Authority: DZ; Algeria
Prior art keywords: hydroxypipecolate; preparation; new; pharmaceutical compositions; compositions containing
Prior art date: 1998-08-12

Application number

DZ990170A

Other languages

English (en)

Inventor

Kim Francis Mcclure

Mark Cari Noe

Michael Anthony Letavic

Louis Stanley Chupak

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-12

Filing date

1999-08-11

Publication date

2003-12-15

1999-08-11 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-12-15 Application granted granted Critical

2003-12-15 Publication of DZ2870A1 publication Critical patent/DZ2870A1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)

DZ990170A 1998-08-12 1999-08-11 Dérivés d'acide hydroxypipécolate-hydroxamique nouveaux, procédé pour leur préparation et compositi ons pharmaceutiques les contenant. DZ2870A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9623298P	1998-08-12	1998-08-12

Publications (1)

Publication Number	Publication Date
DZ2870A1 true DZ2870A1 (fr)	2003-12-15

Family

ID=22256467

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ990170A DZ2870A1 (fr)	1998-08-12	1999-08-11	Dérivés d'acide hydroxypipécolate-hydroxamique nouveaux, procédé pour leur préparation et compositi ons pharmaceutiques les contenant.

Country Status (43)

Country	Link
US (2)	US6329397B1 (fr)
EP (1)	EP1104403B1 (fr)
JP (1)	JP2002522528A (fr)
KR (1)	KR20010085374A (fr)
CN (1)	CN1316995A (fr)
AP (1)	AP2001002070A0 (fr)
AR (1)	AR019241A1 (fr)
AT (1)	ATE325791T1 (fr)
AU (1)	AU766366B2 (fr)
BG (1)	BG105323A (fr)
BR (1)	BR9912909A (fr)
CA (1)	CA2340202C (fr)
CZ (1)	CZ2001484A3 (fr)
DE (1)	DE69931266T2 (fr)
DZ (1)	DZ2870A1 (fr)
EA (1)	EA200100126A1 (fr)
EE (1)	EE200100086A (fr)
ES (1)	ES2263279T3 (fr)
GE (1)	GEP20033117B (fr)
GT (1)	GT199900131A (fr)
HK (1)	HK1040242A1 (fr)
HN (1)	HN1999000131A (fr)
HR (1)	HRP20010098A2 (fr)
HU (1)	HUP0103452A3 (fr)
ID (1)	ID27840A (fr)
IL (1)	IL141030A0 (fr)
IS (1)	IS5813A (fr)
MA (1)	MA26675A1 (fr)
NO (1)	NO20010686L (fr)
NZ (1)	NZ509296A (fr)
OA (1)	OA11594A (fr)
PA (1)	PA8479201A1 (fr)
PE (1)	PE20000951A1 (fr)
PL (1)	PL346041A1 (fr)
SK (1)	SK1872001A3 (fr)
SV (1)	SV1999000123A (fr)
TN (1)	TNSN99156A1 (fr)
TR (1)	TR200100474T2 (fr)
UA (1)	UA59453C2 (fr)
UY (1)	UY25993A1 (fr)
WO (1)	WO2000009485A1 (fr)
YU (1)	YU5201A (fr)
ZA (1)	ZA200101042B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7354894B2 (en)	1998-08-18	2008-04-08	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en)	1998-08-18	2005-01-25	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
WO2000012093A1 (fr) *	1998-08-31	2000-03-09	Merck & Co., Inc.	Procede de traitement des maladies neurodegeneratives
US6509337B1 (en) *	1998-09-17	2003-01-21	Pfizer Inc.	Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1081137A1 (fr)	1999-08-12	2001-03-07	Pfizer Products Inc.	Inhibiteurs sélectifs de l'aggrécanase pour le traitement de l'ostéoarthrite
EP1138680A1 (fr) *	2000-03-29	2001-10-04	Pfizer Products Inc.	Acides gem-substitués alpha-sulfonylamino hydroxamiques comme inhibiteurs de métalloprotease
JP2001322977A (ja) *	2000-05-12	2001-11-20	Kotobuki Seiyaku Kk	ピペコリン酸誘導体及びその製造方法並びにこれを含有する医薬組成物
JP2002105073A (ja) *	2000-09-27	2002-04-10	Shionogi & Co Ltd	新規マトリックスメタロプロテアーゼ阻害剤
BR0207209A (pt)	2001-02-14	2004-01-27	Warner Lambert Co	Inibidores de metaloproteinase de matriz de pirimidina
DOP2002000332A (es)	2001-02-14	2002-08-30	Warner Lambert Co	Inhibidores de piridina de metaloproteinasas de la matriz
DOP2002000333A (es)	2001-02-14	2002-09-30	Warner Lambert Co	Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
PA8539501A1 (es)	2001-02-14	2002-09-30	Warner Lambert Co	Compuestos triazolo como inhibidores de mmp
US6924276B2 (en)	2001-09-10	2005-08-02	Warner-Lambert Company	Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en)	2001-10-12	2005-11-08	Warner-Lambert Company Llc	Alkynylated quinazoline compounds
BR0213233A (pt)	2001-10-12	2005-01-04	Warner Lambert Co	Alcinos inibidores de metaloproteinase de matriz
US6894057B2 (en)	2002-03-08	2005-05-17	Warner-Lambert Company	Oxo-azabicyclic compounds
MXPA04012932A (es) *	2002-06-26	2005-06-03	Japan Bioindustry Ass	Nuevo derivado de azasugar y farmaco que lo contiene como ingrediente activo.
CA2489722A1 (fr) *	2002-07-17	2004-01-22	William Howard Roark	Combinaison d'un inhibiteur alcyne allosterique de la metalloprotease matricielle-13 et de celecoxib ou de valdecoxib
EP1525030A1 (fr) *	2002-07-17	2005-04-27	Warner-Lambert Company LLC	Combinaison d'un inhibiteur alcyne allosterique de metalloproteinase matricielle 13 avec un inhibiteur selectif de cyclooxygenase-2, a l'exception du celecoxib ou du valdecoxib
WO2004014868A2 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Derives de pyrimidine 2,4-diones, utilises comme inhibiteurs de metalloproteinase matricielle
CA2494014A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Derives monocycliques en tant qu'inhibiteurs de metalloproteinases matricielles
PA8578101A1 (es)	2002-08-13	2004-05-07	Warner Lambert Co	Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014923A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Inhibiteurs de metalloprotease bicycliques condenses avec la pyrimidinone
WO2004014378A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Derives de 3-isoquinolinone utilises comme inhibiteurs de metalloprotease de matrice
WO2004014908A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Inhibiteurs de metalloproteinases heterobicycliques
WO2004014909A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Derives fusionnes de la tetrahydropyridine inhibiteurs de la metalloprotease matricielle
AU2003249540A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused bicyclic metalloproteinase inhibitors
WO2004014880A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Derives de chromone inhibiteurs de metalloproteinase de matrice
JP2006504665A (ja)	2002-08-13	2006-02-09	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	マトリックスメタロプロテイナーゼ阻害剤としてのアザイソキノリン誘導体
US20060223884A1 (en) *	2005-03-22	2006-10-05	Nicolas Chapal	Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
BRPI0910034B1 (pt)	2008-03-25	2022-02-08	Affectis Pharmaceuticals Ag	Antagonistas do p2x7r e composições farmacêuticas que os compreendem
SI2243772T1 (sl)	2009-04-14	2012-05-31	Affectis Pharmaceuticals Ag	Novi antagonisti p x r in njihova uporaba
WO2012110190A1 (fr)	2011-02-17	2012-08-23	Affectis Pharmaceuticals Ag	Nouveaux antagonistes p2x7r et leur utilisation
WO2012163456A1 (fr)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Nouveaux antagonistes de p2x7r et leur utilisation
WO2012163792A1 (fr)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Nouveaux antagonistes de p2x7r et leur utilisation
DE202016007195U1 (de)	2016-11-16	2017-11-17	Bernhard Kohler	Strombegrenzende Schalteinrichtung
WO2020160140A1 (fr) *	2019-01-29	2020-08-06	Darsha Llc	Compositions et méthodes pour traiter une maladie pulmonaire avec des inhibiteurs de métalloprotéinase matricielle

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE198326T1 (de) *	1995-04-20	2001-01-15	Pfizer	Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
AU725831C (en) *	1995-12-08	2002-10-17	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
AU741893B2 (en) *	1996-08-28	2001-12-13	Procter & Gamble Company, The	Substituted cyclic amine metalloprotease inhibitors
WO1998033768A1 (fr) *	1997-02-03	1998-08-06	Pfizer Products Inc.	Derives d'acide arylsulfonylaminohydroxamique
CA2280151C (fr) *	1997-02-11	2005-12-13	Pfizer Inc.	Derives de l'acide arylsulfonylhydroxamique
AU7294098A (en) *	1997-05-09	1998-11-27	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

1999
- 1999-05-08 UA UA2001010473A patent/UA59453C2/uk unknown
- 1999-07-30 PA PA19998479201A patent/PA8479201A1/es unknown
- 1999-08-03 YU YU5201A patent/YU5201A/sh unknown
- 1999-08-05 IL IL14103099A patent/IL141030A0/xx unknown
- 1999-08-05 EA EA200100126A patent/EA200100126A1/ru unknown
- 1999-08-05 TR TR2001/00474T patent/TR200100474T2/xx unknown
- 1999-08-05 BR BR9912909-4A patent/BR9912909A/pt not_active Application Discontinuation
- 1999-08-05 AU AU49247/99A patent/AU766366B2/en not_active Ceased
- 1999-08-05 WO PCT/IB1999/001388 patent/WO2000009485A1/fr active IP Right Grant
- 1999-08-05 ID IDW20010327A patent/ID27840A/id unknown
- 1999-08-05 CA CA002340202A patent/CA2340202C/fr not_active Expired - Fee Related
- 1999-08-05 EP EP99933076A patent/EP1104403B1/fr not_active Expired - Lifetime
- 1999-08-05 KR KR1020017001847A patent/KR20010085374A/ko not_active Application Discontinuation
- 1999-08-05 CZ CZ2001484A patent/CZ2001484A3/cs unknown
- 1999-08-05 CN CN99810697A patent/CN1316995A/zh active Pending
- 1999-08-05 OA OA1200100035A patent/OA11594A/en unknown
- 1999-08-05 JP JP2000564939A patent/JP2002522528A/ja not_active Ceased
- 1999-08-05 HU HU0103452A patent/HUP0103452A3/hu unknown
- 1999-08-05 GE GEAP19995744A patent/GEP20033117B/en unknown
- 1999-08-05 ES ES99933076T patent/ES2263279T3/es not_active Expired - Lifetime
- 1999-08-05 EE EEP200100086A patent/EE200100086A/xx unknown
- 1999-08-05 DE DE69931266T patent/DE69931266T2/de not_active Expired - Fee Related
- 1999-08-05 SK SK187-2001A patent/SK1872001A3/sk unknown
- 1999-08-05 PL PL99346041A patent/PL346041A1/xx not_active Application Discontinuation
- 1999-08-05 AT AT99933076T patent/ATE325791T1/de not_active IP Right Cessation
- 1999-08-05 AP APAP/P/2001/002070A patent/AP2001002070A0/en unknown
- 1999-08-05 NZ NZ509296A patent/NZ509296A/en unknown
- 1999-08-09 HN HN1999000131A patent/HN1999000131A/es unknown
- 1999-08-10 AR ARP990103994A patent/AR019241A1/es not_active Application Discontinuation
- 1999-08-10 PE PE1999000807A patent/PE20000951A1/es not_active Application Discontinuation
- 1999-08-11 TN TNTNSN99156A patent/TNSN99156A1/fr unknown
- 1999-08-11 MA MA25730A patent/MA26675A1/fr unknown
- 1999-08-11 SV SV1999000123A patent/SV1999000123A/es not_active Application Discontinuation
- 1999-08-11 DZ DZ990170A patent/DZ2870A1/fr active
- 1999-08-12 US US09/372,946 patent/US6329397B1/en not_active Expired - Fee Related
- 1999-08-12 GT GT199900131A patent/GT199900131A/es unknown
2000
- 2000-01-28 UY UY25993A patent/UY25993A1/es unknown
2001
- 2001-01-16 IS IS5813A patent/IS5813A/is unknown
- 2001-02-07 ZA ZA200101042A patent/ZA200101042B/en unknown
- 2001-02-08 HR HR20010098A patent/HRP20010098A2/hr not_active Application Discontinuation
- 2001-02-09 NO NO20010686A patent/NO20010686L/no not_active Application Discontinuation
- 2001-03-09 BG BG105323A patent/BG105323A/xx unknown
- 2001-12-03 US US10/008,943 patent/US20030008901A1/en not_active Abandoned
2002
- 2002-02-26 HK HK02101437.7A patent/HK1040242A1/zh unknown

Also Published As

Publication number	Publication date
HK1040242A1 (zh)	2002-05-31
MA26675A1 (fr)	2004-12-20
US6329397B1 (en)	2001-12-11
JP2002522528A (ja)	2002-07-23
IS5813A (is)	2001-01-16
HN1999000131A (es)	2000-03-24
WO2000009485A1 (fr)	2000-02-24
HUP0103452A2 (hu)	2002-04-29
YU5201A (sh)	2003-07-07
UA59453C2 (uk)	2003-09-15
SK1872001A3 (en)	2002-08-06
ATE325791T1 (de)	2006-06-15
CA2340202A1 (fr)	2000-02-24
TNSN99156A1 (fr)	2005-11-10
DE69931266D1 (en)	2006-06-14
EE200100086A (et)	2002-08-15
GEP20033117B (en)	2003-11-25
NO20010686D0 (no)	2001-02-09
KR20010085374A (ko)	2001-09-07
CZ2001484A3 (cs)	2002-05-15
AP2001002070A0 (en)	2001-03-31
TR200100474T2 (tr)	2001-06-21
US20030008901A1 (en)	2003-01-09
CA2340202C (fr)	2006-02-07
ID27840A (id)	2001-04-26
PA8479201A1 (es)	2000-09-29
EP1104403A1 (fr)	2001-06-06
UY25993A1 (es)	2000-03-31
ZA200101042B (en)	2002-10-07
ES2263279T3 (es)	2006-12-01
OA11594A (en)	2004-07-11
SV1999000123A (es)	2000-07-06
AU4924799A (en)	2000-03-06
HRP20010098A2 (en)	2002-02-28
PL346041A1 (en)	2002-01-14
EP1104403B1 (fr)	2006-05-10
DE69931266T2 (de)	2007-02-15
AR019241A1 (es)	2001-12-26
EA200100126A1 (ru)	2001-08-27
GT199900131A (es)	2001-02-02
HUP0103452A3 (en)	2002-10-28
BR9912909A (pt)	2001-05-08
NO20010686L (no)	2001-04-09
NZ509296A (en)	2003-10-31
IL141030A0 (en)	2002-02-10
AU766366B2 (en)	2003-10-16
CN1316995A (zh)	2001-10-10
PE20000951A1 (es)	2000-09-27
BG105323A (en)	2001-10-31

Publication	Publication Date	Title
DZ2870A1 (fr)	2003-12-15	Dérivés d'acide hydroxypipécolate-hydroxamique nouveaux, procédé pour leur préparation et compositi ons pharmaceutiques les contenant.
DZ2666A1 (fr)	2003-03-22	Dérivés d'acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ3042A1 (fr)	2004-03-27	Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2416A1 (fr)	2003-01-04	Dérivés d'acide arylsulfonylhydroxamique procédé pour leur préparation et compositions les contenant.
DZ2303A1 (fr)	2002-12-28	Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26620A1 (fr)	2004-12-20	Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr)	2004-12-20	Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2581A1 (fr)	2003-02-22	Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2300A1 (fr)	2002-12-25	Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr)	2002-12-25	Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26471A1 (fr)	2004-12-20	Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26638A1 (fr)	2004-12-20	Derives d'isothiazole nouveaux, procede pour leur preparation et compoositions pharmaceutiques les contenant
DZ2962A1 (fr)	2004-03-15	Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ2745A1 (fr)	2003-09-08	BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2227A1 (fr)	2002-12-25	Dérivés d'indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2753A1 (fr)	2005-09-15	Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
MA26686A1 (fr)	2004-12-20	Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2197A1 (fr)	2002-12-02	Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3045A1 (fr)	2004-03-27	Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3020A1 (fr)	2004-03-20	Acides oxamiques nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.